According to a new report by Washington-based Families USA, senior citizens can expect their drug prices to more than double in the next 10 years. The report is based on figures from the Medicare Current Beneficiary Survey, a household survey of about 12,000 elderly and disabled Medicare users.
According to a new report by Washington-based Families USA, senior citizens can expect their drug prices to more than double in the next 10 years. The report is based on figures from the Medicare Current Beneficiary Survey, a household survey of about 12,000 elderly and disabled Medicare users.
"By every measure, seniors' drug spending is skyrocketing and will continue unabated in the next decade," said Ron Pollack, executive director of Families USA. "With each passing year, the number of drugs provided for seniors is growing quickly, the prices per prescription are rising ever more rapidly, and drug costs are consuming ever-larger portions of seniors' healthcare spending."
Some of the key findings of the report:
•Â Annual spending on prescription drugs per elderly American will grow from $559 in 1992 to an estimated $1,205 in 2000.
•Â The average number of prescriptions per elderly person will grow from 19.6 in 1992 to 28.5 in 2000 and 38.5 in 2010.
•Â The total number of prescriptions for seniors will grow from 648 million in 1992 to more than 1 billion in 2000, and that number is projected to increase to 1.6 billion by 2010.
•Â The average cost per prescription for the elderly will grow from $28.50 in 1992 to $42.30 in 2000. By 2010, the projected average cost per prescription will be $72.94.
•Â Total prescription drug spending for seniors will grow from $18.5 billion in 1992 to $42.9 billion in 2000, an increase of 132%. By 2010, that spending is projected to reach $113.6 billion.
•Â The portion of healthcare spending for seniors devoted to prescription drugs will grow from 7.4% in 1992 to 10% in 2000 and a projected 13.3% in 2010.
As drug costs increase, private insurance coverage is not expected to alleviate the problem. The report notes that nearly half of all Medicare beneficiaries - 18.4 million people - do not have year-round prescription drug insurance coverage.
The new report was released in the midst of the growing debate over how to guarantee access to prescription drugs. The Clinton administration has proposed a Medicare prescription drug benefit, while the Republican Congressional leadership supports legislation subsidizing private insurance companies to provide drug coverage. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
FDA Approves AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
January 17th 2025Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously untreated mantle cell lymphoma.